<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256618</url>
  </required_header>
  <id_info>
    <org_study_id>UMIN000014903</org_study_id>
    <nct_id>NCT02256618</nct_id>
  </id_info>
  <brief_title>Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy</brief_title>
  <official_title>A Pilot Feasibility and Safety Study of Autologous Umbilical Cord Blood Cell Therapy in Infants With Neonatal Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neonatal Encephalopathy Consortium, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Osaka City University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yodogawa Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kurashiki Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osaka City General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saitama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Child Health and Development, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tokyo Women's Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neonatal Encephalopathy Consortium, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to test feasibility and safety of intravenous infusion of autologous
      umbilical cord blood cells in the first 72 hours after birth if a neonate is born with signs
      of encephalopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter pilot study to evaluate the feasibility and safety of intravenous
      infusions of autologous (the patient's own) umbilical cord blood cells in term gestation
      newborns with neonatal encephalopathy (hypoxic-ischemic encephalopathy). If a neonate is born
      with signs of moderate to severe encephalopathy and cooled for the encephalopathy, the
      neonate can receive their own non-cryopreserved volume- and red blood cell-reduced cord blood
      cells. The cord blood cells are divided into 3 doses and infused at 12-24, 36-48, and 60-72
      hours after the birth. Infants will be followed for safety and neurodevelopmental outcome up
      to 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>first 30 postnatal days</time_frame>
    <description>Adverse event rates (combined rate of death, continuous respiratory support, and continuous use of vasopressor) will be compared between the cell recipients and historical controls at 30 days of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>18 months</time_frame>
    <description>Neuroimaging at 12 months of age and neurodevelopmental function at 18 months of age will be compared between the cell recipients and historical controls.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Hypoxic-ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous umbilical cord blood cells</intervention_name>
    <description>Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused</description>
    <arm_group_label>Cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants are eligible if they meet all the following inclusion criteria except 4.

          1. ≥36 weeks gestation

          2. Either a 10-minute Apgar score ≤5, continued need for resuscitation for at least 10
             minutes, or severe acidosis, defined as pH &lt;7.0 or base deficit ≥16 mmol/L in a sample
             of umbilical cord blood or any blood during the first hour after birth

          3. Moderate to severe encephalopathy (Sarnat II to III)

          4. A moderately or severely abnormal background amplitude-integrated EEG (aEEG) voltage,
             or seizures identified by aEEG, if monitored

          5. Up to 24 hours of age

          6. Autologous umbilical cord blood available to infuse within 3 days after birth

          7. A person with parental authority must have consented for the study.

        Exclusion Criteria:

          1. Known major congenital anomalies, such as chromosomal anomalies, heart diseases

          2. Major intracranial hemorrhage identified by brain ultrasonography or computed
             tomography

          3. Severe growth restriction, with birth-weight less than 1800 g

          4. Severe infectious disease, such as sepsis

          5. Hyperkalemia

          6. Outborn infants (Infants born at hospitals other than the study sites)

          7. Volume of collected cord blood &lt;40 ml

          8. Infants judged critically ill and unlikely to benefit from neonatal intensive care by
             the attending neonatologist
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haruo Shintaku, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka City University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yodogawa Christian Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>533-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka</city>
        <zip>545-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Tsuji M, Taguchi A, Ohshima M, Kasahara Y, Sato Y, Tsuda H, Otani K, Yamahara K, Ihara M, Harada-Shiba M, Ikeda T, Matsuyama T. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience. 2014 Mar 28;263:148-58. doi: 10.1016/j.neuroscience.2014.01.018. Epub 2014 Jan 18.</citation>
    <PMID>24444827</PMID>
  </reference>
  <reference>
    <citation>Ohshima M, Taguchi A, Tsuda H, Sato Y, Yamahara K, Harada-Shiba M, Miyazato M, Ikeda T, Iida H, Tsuji M. Intraperitoneal and intravenous deliveries are not comparable in terms of drug efficacy and cell distribution in neonatal mice with hypoxia-ischemia. Brain Dev. 2015 Apr;37(4):376-86. doi: 10.1016/j.braindev.2014.06.010. Epub 2014 Jul 14.</citation>
    <PMID>25034178</PMID>
  </reference>
  <reference>
    <citation>Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004 Aug;114(3):330-8.</citation>
    <PMID>15286799</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neonatal encephalopathy</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>newborn infants</keyword>
  <keyword>neonates</keyword>
  <keyword>umbilical cord blood cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

